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Survival and multiplication of Burkholderia cepacia 
within respiratory epithelial cells 
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Objective: To investigate the ability of both clinical and environmental strains of Burkholderia cepacia, along with control 
strains of Pseudomonas aeruginosa and Escherichia coli, t o  invade a respiratory epithelial cell line, A549. 
Methods and Results: Using a double imrnunofluorescence labeling technique, a clinical strain of 5. cepacia, C1359, and 
the clonally related strains A509 and J2315, were shown to  invade A549 cells at a high level (2-8% A549 cells invaded) 
compared to  environmental strains of 5. cepacia NCTC 10661 and NCTC 10743 (0.5-1% of A549 cells invaded). Control 
strains of FI aeruginosa PA01 and E. coli C600 did not appear to be able to invade respiratory epithelial cells using this 
method. Ceftazidime protection assays revealed that B. cepacia C1359 and NCTC 10743 were able to survive and multiply 
within A549 cells for 224 h. In contrast, B. cepacia NCTC 10661, t? aeruginosa PA01 and E. coli C600 failed to  multiply 
within A549 cells, showing a significant decrease in numbers after 24 h. 
Conclusions: The ability to survive and multiply within respiratory epithelial cells may be an important virulence factor 
of B. cepacia infection in cystic fibrosis. 
Key words: Burkholderia cepacia, Pseudomonas aeruginosa, invasion, multiplication, respiratory epithelial cells, 
immunofluorescence 
INTRODUCTION 
Biivkholdcriu (formerly Pseudornonas) repacia was first 
described as a plant pathogen causing soft rot in onions 
[ l ] ;  however, it has been increasingly recognized as an 
important opportunistic pathogen associated with 
sepsis in immunocoinpromised hosts and pulmonary 
infection in patients with cystic fibrosis (CF) [2-41. 
Although the susceptibility of CF patients to revpiratory 
tract colonization by Staphylococcus airreus, Reudomonus 
acwginosa and Hucmopliilns irrrzrenzae is well documented 
15-91, colonization with B. repacia has emerged as a 
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problem among CF patients over the last 15-20 years. 
The clinical management of CF patients is hampered 
by the resistance of many strains of B. cepacia to multiple 
antibiotics, and this is further complicated by the fact 
that in vitro susceptibility to antimicrobials is not 
always indicative of a favorable clinical outcome. Three 
outcomes have been associated with colonization by 
B. cepacia; chronic asyniptomatic carriage, progressive 
deterioration over a prolonged period, or a rapidly fatal 
necrotizing pneumonia [lo]. I t  is unclear whether these 
different outcomes are the result of the existence of 
subpopulations of B. cepacia with increased pathogenic 
potential or are related to host factors. 
Comparatively little is known of the putative 
virulence factors of B. cepuciu, especially those ofirnport- 
ance in the development of necrotizing pneumonia. 
Burns et a1 first suggested that B. repuria was capable of 
invading respiratory epithelial cellv [I 2 1 .  More recently, 
these authors used an antibiotic protection assay to 
demonstrate that B. cepacia is not only capable of intra- 
cellular inva$ion, but can also replicate intracellularly 
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[12]. This, of course, will confer an advantage to the 
bacterium, as it will be protected from both the host 
immune system and antimicrobials, which do not 
achieve significant intracellular concentrations. We 
have examined the ability of a small number of both 
clinical and environmental strains of B. cepacia to invade 
and multiply within A549 cells using an antibiotic 
protection assay and, in addition, a double immuno- 
fluorescence technique. 
MATERIALS AND METHODS 
Bacteria 
The bacterial strains used in this study are shown in 
Table 1. B. cepacia J2315 was the initial strain isolated 
(index CF patient, outcome unknown). This strain was 
termed the ‘epidemic’ strain and was subsequently 
isolated from a CF patient who died (C1359) and more 
recently from another CF patient (A509, patient 
healthy) [13,14]. All strains were grown overnight in 
brain-heart infusion (BHI; Unipath Ltd, Basingstoke, 
UK) at 37OC with shaking at 160 rev/min. Freshly 
prepared 20-mL volumes of BHI were inoculated to an 
optical density of 0.1 at 600 nm, and growth was 
followed by measuring the optical density at 600nm 
every hour for 24 h. All strains were grown as above 
until the cells reached mid-exponential phase, when 
they were harvested and washed in freshly prepared 
tissue-culture medium. Alternatively, mid-exponential- 
phase cells were frozen in 20-mL volumes of BHI and 
stored at -70°C until required. Viable bacteria were 
determined by plating 0.1-mL volumes of 10-fold serial 
dilutions on IsoSensitest agar (Unipath Ltd). Colonies 
were counted after incubation for 24-48 h at 37OC, 
depending on strain. 
Culture of A549 respiratory epithelial cells 
A549 respiratory epithelial cells were grown in Rosslyn 
Park Memorial Institute (RPMI) 1640 (Gibco BRL, 
Paisley, UK) plus 5% (v/v) fetal bovine serum 
(Gibco BRL), 20 mM N-(2-hydroxyethyl)piperazine- 
N’-(2-ethanesulfonic acid) (HEPES; Gibco BRL) and 
2 mM L-glutamine. Benzylpenicillin (60 mg/L) and 
streptomycin (100 mg/L) were added to the medium. 
Cells were incubated in a humid zltmosphere of air 
containing 5% (v/v) C02 at 37OC: for 48 h. A549 
monolayers were prepared on sterile glass coverslips or 
in 24-well tissue-culture plates by seeding cells at  
5 X 104/mL (1.5 mL/well) and incubating in an 
atmosphere of air continuing 5% (v/v) CO2 at 37OC 
for 36 h. Monolayers were washed twice with pre- 
warmed Hank’s balanced salt solution (Gibco BRL), 
supplemented with 20 mM HEPES, and the medium 
as replaced with freshly prepared RPiWI 1640 (without 
antibiotics). 
Infection of A549 monolayen 
A549 monolayers were infected with a suspension of 
washed bacteria adjusted to give a multiplicity of 
infection of approximately 10 bacteria per respiratory 
epithelial cell. Infected monolayers u’ere incubated in a 
humid atmosphere of air containing 5% (v/v) C 0 2  at 
37°C for 2 h. 
lmmunolabeling of intracellular and extracellular bacteria 
A method combining antibody labeling of bacteria and 
fluorescence microscopy was adapted from van Putten 
et a1 [15]. This double immunostaining procedure 
labels intracellular bacteria with a different fluoro- 
chrome to extracellular bacteria and therefore intra- 
cellular bacteria are stained a d i fkent  color when 
viewed using fluorescence microscopy. 
Table 1 
Strain Description Source 







C600 (NCIMB 11459) 




CF patient 1, epidemic strain [13,14] 
CF patient 2, epidemic strain [13,14] 





CF patient 4, mucoid 
University of Edinburgh Medical School 
As above 
As above 
NCTC, Colindale, UK 
NCTC, Cohndale, UK 
NCIMB, Aberdeen, UK 
NCTC, Colindale, UK 
St James’s University Hospital, Leeds, 
UK 
’Identified by restriction fragment length polymorphism by pulsed-field gel electrophoresis and ribotype analysis. NCTC, 
National Collection of Type Cultures; ATCC, American Type Culture Collection; NCIMB, National Collection of 
Industrial and Marine Bacteria. 
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Kabbit polyclonal antibodies were raised against B. 
repacia C1359. Monolayers of A549 cells were prepared 
and infected as described earlier, rinsed in phosphate- 
buffered saline (PBS) and fixed by incubating with 2% 
(v/v) parafornialdehyde for 30 inin at room temper- 
ature. Coverslips were incubated with polyclonal 
antibody for 45 niin in a moist chamber, and unbound 
antibody was removed by three 5-min washes with 
PUS. Extracellular bacteria were labeled by incubating 
with a Texas Red-conjugated ligand (goat anti-rabbit 
IgG-Texas Red, A. M. S. Biotechnology, Witney, UK) 
for 30 min. Thus, extracellular bacteria appeared 
red when viewed with a fluorescence microscope. 
Unbound conjugate was removed by washing three 
times with PBS. The A549 epithelial cell membranes 
were permeabilized by incubating with 0.3% (v/v) 
Triton X-100 for 15 min, and excess detergent was 
removed by washing in PBS for 5 min. Coverslips were 
then incubated with the same polyclonal antibody for 
45 niin. and unbound antibody was removed by wash- 
ing three times with PBS. lntracellular bacteria were 
labeled by incubation with a fluorescein isothiocyanate 
(F1TC)-conjugated ligand (swine anti-rabbit IgG- 
FITC, Dako Ltd, High Wycombe, UK) for 30min. 
This labeled the intracellular bacteria green when 
viewed with a fluorescence microscope. Unbound 
conjugate was removed by washing three times with 
PBS, and the coverslips were mounted on glass slides 
and sealed with clear nail polish. Slides were viewed 
using a Zeiss fluorescence microscope equipped with a 
dual filter (for viewing FITC- and Texas Red-labeled 
monolayers simultaneously). Slides were photographed 
using Fuji Provia 1600 color reversal film. 
Control strains included in the immunofluor- 
escence assay were Eschericlzia coli C600, a non-invasive 
laboratory strain [16], and I? aerugirzosa PA01 (ATCC 
1.5692). Antisera against these two organisms were 
purchased cominercially from I h k o  Ltd, and Cheiilicon 
International Ltd, Harrow, UK, respectively. 
Ceftazidime protection assay 
As the majority of clinical strains of B. cepncia were 
resiutant to gentaniicin, a modification of the genta- 
niicin protection assay [17,18], commonly used to 
measure bacterial penetration of eukaryotic cells. was 
necessary. All strains of B. cepacin and control strains 
uwd in this study were found to be susceptible to 
ceftazidime, determined by diqk diffusion methodc, and 
'is the intracellular penetration of p-lactam antibiotics 
such a ceftazidinie is poor, it was substituted for genta- 
niicin in the following assay. Monolayers of A549 cells 
were prepared in 24-well tissue-culture plates and 
infected as described above. After 2 h of incubation at 
37"C, infected cells were washed three times with PBS 
to remove adherent bacteria, and the medium was 
replaced by freshly prepared RPMI 1640 (plus HEPES) 
containing 50 mg/L ceftazidime (Sigma Chemical 
Co.). This prevented further growth of extracellular 
bacteria. The time point immediately preceding the 
addition of ceftazidime was referred to as time zero 
(TO). At this and subsequent time points (2 h, 4 h, 
24 h), the medium was removed from duplicate wells, 
and the monolayers washed twice with PBS and lysed 
with PBS containing 0.3% (v/v) Triton X-100. The 
numbers of bacteria (CFUIwell) were determined by 
plating appropriate dilutions of the lysate on Iso- 
Sensitest agar and incubating for 36-48 h at 37°C. Each 
strain was tested in duplicate in three independent 
experiments. The number of bacteria at  TO, i.e. at the 
end of the 2 h infection period, was taken to represent 
the number of bacteria associated with the monolayer 
(i.e. attached to the surface or at some stage of intern- 
alization). However, the numbers of bacteria at T2 (2 h 
after the completion of the infection period), and 
subsequent time points, were considered to represent 
intracellular bacteria only. 
RESULTS 
Viability of bacteria 
Viable bacteria were determined before and after 
freezing at -70°C. Freezing was found to niarkedly 
affect the numbers of viable bacteria of all strains except 
those of clinical origin. Therefore, all strains except 
C1359 were grown to nid-exponential phase on the 
day of the assay. 
lrnmunolabeling of intracellular and extracellular bacteria 
Preliminary results suggested that B. cepacin C1359 
was able to invade A549 respiratory epithelial cells at 
a high level (2-8?4 of A549 cells invaded). Figure 1 
shows antibody-labeled H. c-epncin C1359-infected 
A549 monolayers. The intracellular and extracellular 
bacteria were labeled with secondary antibodies 
conjugated to FITC and Texas Red, respectively. Green 
bacteria were clearly visible inside A549 respiratory 
epithelial cells. Red extracellular bacteria were also 
observed. The specificit). of the antibody labeling 
was investigated and the results suggested that all 
FITC-labeled bacteria were situated in an intracellular 
location. Subsequent experiments revealed that B. 
ccprin strains A509 and 52315 were also able to invade 
respiratory epithelial cells at a level similar to B. c r p c i n  
C1359 (2-696 of epithelial cells invaded; data riot 
shown). Although the e'nvironniental strains of B. 
cepnrin NCTC 10661 (Figure 2) and NCTC 10743 
were able to invade A549 cells, this was at a substantially 
lower level (0.1-1% of A549 cells invaded; data not 
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Figure 1 Double inimunofluorescence assay showing A549 respiratory epithelial cells infected with the clinical strain of B. 
cepacia, C1359 (X200 magnification). Extracellular bacteria are labeled with Texas Red-conjugated secondary antibodies and 
appear red-orange. Intracellular bacteria are labeled with FITC-conjugated secondary antibodies and appr’ar green. 
Figure 2 Double inmiunofluorescence assay showing A549 respiratory epithelial cells infected with the ienvironmental strain 
of B. cepacia, N C T C  10661 (X200 magnification). The numbers of green intracellular bacteria are significantly reduced 
compared to B. cepacia C1359-infected A549 monolayers (Figure 1). 
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Figure 3 Double immunofluorescence assay showing A549 respiratory epithelial cells infected with E. mli strain C600 
(X  200 magnification). No intracellular green bacteria are presmt. 
shown). In contrast, it was found that the laboratory 
strain of E. coli C600 (Figure 3) and l? aenrginosa PA01 
were not able to invade A549 cells. 
Ceftazidime protection assay 
The capacity of B. cepacia to enter the respiratory 
epithelial cell line A549 and to grow intracellularly was 
evaluated using this in vitro model. Figure 4 shows the 
kinetics of infection of A549 cells with B. cepacia strains 
C1359, N C T C  10661 and N C T C  10743, and the 
control strains of l? aeruginosa (Pa01 and CFPA) and E. 
roli (C600). B. cepacia C1359 was able to invade the 
respiratory epithelial cells. After infection, the numbers 
of viable bacteria decreased over a 4-h period that 
corresponded with the killing of extracellular cell- 
associated bacteria by ceftazidime. This was followed by 
a 10-fold increase in bacterial numbers within 20 h due 
to intracellular multiplication of B. cepacia C1359. B. 
reparia NCTC 10743 followed a similar pattern of 
infection with an initial decline in numbers between 0 
and 4 h followed by an eight-fold increase in numbers 
within 20 h. In contrast, the numbers of viable B. 
cepacia NCTC 10661 decreased 3.6-fold a t  4 h and 
two-fold at  24 h postinfection. 
In addition, Figure 4 shows that although the 
control strains of I? aeruginosa (PA01 and CFPA) and E. 
coli (C600) were able to penetrate A549 respiratory 
epithelial cells, they failed to multiply intracellularly 
and the numbers of viable bacteria decreased steadily 
over time. The numbers of viable l? aenrginosa Pa01 
organisms fell 15-fold between 2 and 4 h and 47-fold 
between 4 and 24 h. Similarly, the numbers of I! 
aeruginosa CFPA organisms fell five-fold between 2 and 
4 h and 138-fold between 4 and 24 h. E. coli C600 
showed similar kinetics of intracellular survival, with 
the numbers of viable bacteria decreasing at 4 h and 
24 h. 
In order to determine whether the intracellular 
bacteria recovered after 24 h were resistant to 
ceftazidime, several colonies of each strain were selected 
from the agar plates and tested by disk diffusion for 
susceptibility to ceftazidime. All strains were found to 
be sensitive to ceftazidime after 24 h of incubation. 
These results suggest that the bacteria recovered 
throughout the ceftazidime protection assay were 
intracellular bacteria and not cefiazidime-resistant 
mutants. 
Statistical analysis 
The results of the ceftazidime protection assay were 
analyzed by two-way analysis of variance (ANOVA). 
Minimum significant differences (MSD) between 
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Figure 4 Infection of A549 respiratory epithelial cells with B. cepacia strains C1359, NCTC 10661 and NCTC 10743, and 
control strains I? aeruginosa PA01 and CFPA and E. coli C600. The results are expressed as loglo mean viable bacteria per well 
(mean of duplicate wells per time point) &95% confidence limits. 
means (n=8) were calculated by the T-method [19]. 
This analysis revealed that the number of viable R. 
cepacia organisms was significantly higher @<0.05) than 
the number of viable control organisms, I? aemginosa 
2nd E. colj, after 24 h (Figure 5). addition, there was 
a statistically significant decrease in the number of 
viable bacteria (control strains only) from 4 h to 24 h 
@<0.05; Figure 5). 
DISCUSSION 
The emergence of B. cepacia as an important Pulmonary 
Pathogen within the CF PoPulation has led many 
centers to introduce policies whereby individuals 
colonized or infected by this bacterium are segregated 
from other CF patients, with social and psychological 
consequences [20]. There is, therefore, a need to 
456 Cl in ica l  M i c r o b i o l o g y  and  In fec t i on ,  Vo lume 4 Number  8, August  1998 
characterize the epidemiology of this bacterium, and 
also to identify its virulence factors. It  can be inferred 
from the natural history of €3. cepacia sepsis in CF  patients 
that there are interstrain differences in virulence, with 
some strains causing chronic pulmonary disease and 
others being carried asymptomatically [13]. The ability 
to distinguish between ‘virulent’ and ‘non-virulent’ 
ctrains may ultimately permit the relaxation of stringent 
policies in the CF population. It has been suggested 
that B. cepucia can only cause infection where severe 
lung damage already exists, or that B. cepacia requires 
the presence of other organisms, especially P aenqinosa, 
with which it is reported to act in synergy [6,21]. 
However, more recently it has been observed that B. 
repacia was able to cause a rapidly fatal pneumonia in 
previously healthy non-CF lungs, following lung 
transplantation, in the absence of other pathogens [22]. 
In addition, at  one CF center in Edinburgh, only 62%) 
of patients colonized with B. cepacin were co-colonized 
with J? uwuginoru I 131. B. cepacia has also been associated 
with pneumonic illness in individuals with chronic 
granuloniatous disease [23] and, more recently, has 
been reported as an etiologic agent of pneumonia 
in apparently immunoconipetent patients [24]. This 
suggest that B. cepacia possesses virulence factors that 
play an important role in respiratory tract infection; 
however, impaired host defense systems may allow 
organisms with low levels of virulence to cause infec- 
tions in these individuals. Knowledge of the virulence 
factors of B. cepacia is limited [as]. B. r e p a h  does not 
produce elastase, exoenzynie S, exotoxin A or alginate, 
which are niajor virulence factors expressed by I! 
aeruginosa in the pathogenesis of CF lung infection [26]. 
Lipase production has been described but the purified 
enzyme has been shown to be neither cytotoxic to cell 
cultures, nor toxic when injected into mice 1271. 
Purified extracellular protease was shown to be toxic to 
rat lungs on intratracheal installation [2X], although 
many strains of B. ceparia show no proteolytic activity 
and the precise role of this enzyme in the pathogenesis 
of pulmonary sepsis is unclear. Lipopolysaccharide 
from some clinical isolates has been shown to be toxic 
when injected intraperitoneally into mice [29], and it 
has been suggested that lipopolysaccharide may be 
responsible for the pulmonary tissue damage associated 
with necrotizing pneumonia caused by this organism 
[30]. Other virulence factors of B. cepuciu include 
siderophores [311 and heniolysin 1321; however, the 
pathogenic role of these remains uncertain. I t  has been 
reported that B. repucin strains bind to respiratory 
epithelial cells using pili located on the cell surface 
by two different adhesin receptor systems; one ir  
independent of bacterial piliation, and the other is 
mediated by a 22-kDa pilus-associated adhesin which 
binds to respiratory niucins 133,341. I n  addition, recent 
reports suggest the existence of at least five differ- 
ent structural types of pilin adhesins 135,361. These 
moieties permit adherence of B. cepucia to the niuco- 
*,** significantly different (p<O 05) 
* 





control strains ( P  ncruginoso PA01 and CFPA and E. roli ChOO). The results are expressed as l o g i ~  mean viable bacteria per 
\\,ell ?95‘%1 confidence limits. *, mean CFU per well €3. ccpacin is significantly different (p i0 .05)  from mean CFU per well 
controls at  T24; **, decrease in bacterial number is significantly different @<0.05) from 4 h to 24 h (control strains). 
Infection of A549 respiratory epithelial cell$ with B. cepa(ia (C1359, NCTC 10661 and NCTC 10743) and 
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cdiary apparatus and, possibly, other bacteria, and may 
play a role in the early stages of colonization and 
infection by the bacterium. However, the relationship 
between these adhesins and the ability of some strains 
to produce fulminant pulmonary infection remains to 
be characterized. 
Invasion of respiratory epithelial cells as a putative 
virulence factor of B. cepacia was first reported by Burns 
et a1 [ l l ] ,  who demonstrated using a clinical CF isolate 
that invasiveness was maximal when the bacteria were 
in early exponential phase. Invasion was not affected by 
inhibitors of protein synthesis, but was decreased in the 
presence of cytochalasin D, which inhibited micro- 
filament formation [37]. This work used only a single 
strain of B. cepacia and employed electron microscopy 
to determine invasiveness, which is relatively expensive 
and does not lend itself to the examination of a larger 
number of strains. Subsequently, Burns et al, using a 
quantitative method based on an antibiotic protection 
assay, coupled with electron microscopy studies, have 
demonstrated intracellular invasion and survival of B. 
cepacia within A549 cells [12]. This investigation was 
limited to a single clinical strain from a patient with 
necrotizing pneumonia and a laboratory strain which 
had a 0.8-kb deletion from one of three circular 
replicons present in B. cepacia. We have developed a 
double immunofluorescent assay that readily permits 
screening of larger numbers of strains and included two 
strains of environmental origin to determine whether 
invasiveness was a property manifested exclusively by 
clinical strains. This assay is a useful alternative to the 
ceftazidime and gentamicin protection assays which are 
frequently used in the investigation of invasiveness, as it 
does not rely on the antimicrobial susceptibility profiles 
of the bacterial strains under investigation. Moreover, 
it has recently been demonstrated that gentamicin, 
especially in high concentrations (>5 mg/L), may 
accumulate within cells 1381. The immunofluorescence 
assay is, therefore, particularly suited to the study of 
multiply-resistant bacteria such as B. cepacia, although 
it appears to be less sensitive than the antibiotic protec- 
tion assays. Using this immunofluorescence technique, 
we have shown that clinical strains of B. cepacia are able 
to invade A549 respiratory epithelial cells at a high 
level. It has also been shown that environmental strains 
of B. cepacia are capable of invading A549 cells, but at  
a lower level. With this assay, control strains of I? 
aeruginosa (PAO1, CFPA) and E. coli (C600) did not 
appear to be invasive for A549 cells. 
Nevertheless, it was also necessary to determine 
whether intracellular B. cepacia organisms were viable 
and able to multiply. Using the ceftazidime protection 
assay, we confirmed that clinical strain B. cepacia C1359 
and environmental strain NCTC 10743 were able to 
invade respiratory epithelial cells arid then to multiply 
in an intracellular location. Statistical analysis showed 
that, 24 h after infection, the numbers of viable B. 
cepacia were significantly higher th.m the numbers of 
control organisms. The environmental strain of B. 
cepacia NCTC 10661 was able to imade the A549 cells; 
however, it was not able to replicate in an intracellular 
location. The control strains of I? awuginosa (PA01 and 
CFPA) and E. coli were also observed within respiratory 
epithelial cells, but after 2 h numbers started to decline 
and both organisms were unable to replicate intra- 
cellularly. interestingly, Chi et a1 1391 also reported 
invasion of A549 respiratory epithelial cells by I? 
aeruginosa PAK; however, their experiments were 
terminated after only 4 h, and therefore they were 
unable to observe the fate of invading I? aeruginosa PAK. 
Burns et a1 also noted some invasion of A549 cells, 
albeit at very low levels, by a control strain of E. coli 
[12]. The double immunofluorescence test could, 
therefore, be argued to be more discriminatory in 
identifying truly invasive bacteria. 
The ability of B. cepacia to invade respiratory 
epithelial cells is important, not only in terms of patho- 
genicity, but also because it may explain the problems 
experienced in the management of CF patients, 
specifically those whose strains exhibit antibiotic- 
sensitive profiles in vitro, but show a poor clinical 
response when treated with those antibiotics. For 
example, those patients colonized by B. cepacia strains 
that are sensitive to ceftazidime in vitro may still show 
a disappointing response to this antibiotic, as ceftazi- 
dime penetrates mammalian cells p,aorly and therefore 
may not reach intracellular bacteri,i in concentrations 
high enough to kill them. Our findings may have 
significant implications for the development of novel 
therapeutic strategies for the treatment of B. cepacia- 
related sepsis, e.g. liposomal ceftazidime. Other investi- 
gators have shown potential therapeutic benefits in 
treating pulmonary sepsis using lipc'somal aminoglyco- 
sides [40]. Our findings contribute further evidence in 
support of the hypothesis, first advzmced by Burns and 
colleagues [11,12,37], that B. cepai:ia can behave as a 
facultative intracellular pathogen. Elutler et a1 reported 
1411 that B. cepacia isolates from CF patients with 
bacteremic pneumonic illness were frequently suscept- 
ible to the bactericidal effects of hurnan serum, suggest- 
ing that the bacterium may be capable of surviving 
within professional phagocytes. Evidence that CF 
isolates are more likely to produce 'iatalase (an enzyme 
of importance in resisting the bactericidal activity of 
neutrophils) than non-CF strains is also important in 
this respect [42]. Furthermore, poor prognosis of B. 
cepacia-related sepsis in individuals with compromised 
T-cell immune responses further supports the hypo- 
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thesis that B. cepacia behaves as a facultative intracellular 
pathogen [23]. Interestingly, another member of the 
genus Burkholderia, B. pseudomallei, has been shown to 
survive within human phagocytes and thus may also 
behave as a facultative intracellular pathogen [43]. 
We now intend to examine the ability of a wider 
range of B. cepacia strains to invade both transformed 
and primary respiratory epithelial cells. In addition, we 
plan to investigate whether invasiveness is modified 
under conditions similar to those of the CF lung, such 
as increased osmolarity of growth medium and concen- 
tration of divalent cations. 
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